25-Hydroxyvitamin D3 -enhanced PTPN2 positively regulates periodontal inflammation through the JAK/STAT pathway in human oral keratinocytes and a mouse model of type 2 diabetes mellitus

J Periodontal Res. 2018 Jun;53(3):467-477. doi: 10.1111/jre.12535. Epub 2018 Mar 8.

Abstract

Background and objective: Periodontitis is an increasingly prevalent complication of diabetes mellitus (known as diabetes mellitus-associated periodontitis), and 25-hydroxyvitamin D3 (25VD3 ) was recently found to be a critical regulator of innate immunity in this disease, but the underlying mechanisms remain poorly understood. T-cell protein tyrosine phosphatase non-receptor type 2 (PTPN2) is a potential downstream protein of the 25VD3 /vitamin D receptor pathway. The aim of this study was to investigate the regulation of PTPN2 in periodontal inflammation in diabetes mellitus-associated periodontitis.

Material and methods: Porphyromonas gingivalis-infected db/db mice were treated with 25VD3 . Their fasting blood glucose and body weight were monitored every other week, and the levels of alveolar bone loss and serum inflammatory cytokines (tumor necrosis factor-α, interferon-γ and interleukin-6) were determined at the time of killing. The effect of PTPN2 on human OKF6-TERT2 oral keratinocytes was examined through the knockout of PTPN2 using the CRISPR/Cas9 knockout plasmid. The expression levels of the PTPN2, vitamin D receptor and JAK1/STAT3 signaling proteins in the gingival epithelium and OKF6-TERT2 cells were determined through western blot and immunohistochemical analyses.

Results: After 25VD3 treatment, db/db mice exhibited alleviated serum inflammatory cytokines and alveolar bone loss, and 25VD3 -enhanced PTPN2 expression decreased the expression of the JAK1/STAT3 signaling proteins in the gingival epithelium. Analyses of human oral keratinocytes showed that 25VD3 increased the expression of PTPN2, which dephosphorylates protein substrates in the JAK1/STAT3 signaling pathway.

Conclusion: PTPN2 contributed to a decrease in periodontal inflammation in type 2 diabetes mellitus via dephosphorylate protein substrates in the JAK1/STAT3 signaling pathway after 25VD3 treatment in human oral keratinocytes and a mouse model of type 2 diabetes mellitus. A thorough understanding of PTPN2 and its involvement in inhibiting inflammation might provide alternative therapeutic approaches for the pathogenesis and treatment of diabetes mellitus-associated periodontitis.

Keywords: JAK; STAT; PTPN2; Vitamin D3; diabetes mellitus-associated periodontitis.

MeSH terms

  • Alveolar Bone Loss / drug therapy
  • Alveolar Bone Loss / metabolism
  • Alveolar Bone Loss / microbiology
  • Alveolar Bone Loss / pathology
  • Animals
  • Blood Glucose / metabolism
  • Body Weight
  • Calcifediol / pharmacology*
  • Cell Line
  • Cytokines / blood
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetes Mellitus, Experimental / metabolism
  • Diabetes Mellitus, Experimental / microbiology
  • Diabetes Mellitus, Experimental / pathology
  • Diabetes Mellitus, Type 2 / complications*
  • Gene Knockout Techniques
  • Humans
  • Janus Kinases / metabolism*
  • Keratinocytes / drug effects*
  • Keratinocytes / metabolism
  • Keratinocytes / microbiology
  • Keratinocytes / pathology
  • Male
  • Mice
  • Mice, Inbred Strains
  • Periodontitis / drug therapy*
  • Periodontitis / metabolism
  • Periodontitis / microbiology
  • Periodontitis / pathology
  • Porphyromonas gingivalis / isolation & purification
  • Protein Tyrosine Phosphatase, Non-Receptor Type 2 / genetics
  • Protein Tyrosine Phosphatase, Non-Receptor Type 2 / metabolism*
  • Receptors, Calcitriol / biosynthesis
  • STAT Transcription Factors / metabolism*
  • Signal Transduction / drug effects

Substances

  • Blood Glucose
  • Cytokines
  • Receptors, Calcitriol
  • STAT Transcription Factors
  • Janus Kinases
  • PTPN2 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 2
  • Ptpn2 protein, mouse
  • Calcifediol